Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )
ClinicalTrials.gov Identifier:
NCT00897754
First received: May 9, 2009
Last updated: May 17, 2017
Last verified: May 2017

May 9, 2009
May 17, 2017
July 24, 2007
February 1, 2009   (Final data collection date for primary outcome measure)
  • Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Time Frame: 1 month ]
  • Gene expression as measured by tissue microarrays [ Time Frame: 1 month ]
  • Splice form expression as measured by reverse transcriptase-PCR [ Time Frame: 1 month ]
  • VEGF165b protein expression as measured by ELISA [ Time Frame: 1 month ]
  • Mean scores for VEGFb and pan-VEGF gene expression by IHC
  • Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios
  • Gene expression as measured by tissue microarrays
  • Splice form expression as measured by reverse transcriptase-PCR
  • VEGF165b protein expression as measured by ELISA
Complete list of historical versions of study NCT00897754 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.

PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

OBJECTIVES:

  • Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.

OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Samples submitted for research from patients participating in E3200
Colorectal Cancer
  • Genetic: gene expression analysis
  • Genetic: protein expression analysis
  • Genetic: reverse transcriptase-polymerase chain reaction
  • Other: immunoenzyme technique
  • Other: immunohistochemistry staining method
  • Other: immunologic technique
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
February 1, 2009
February 1, 2009   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum

    • Receiving bevacizumab on clinical trial E-3200

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00897754
CDR0000560986
ECOG-E3200T2
Not Provided
Not Provided
Not Provided
Not Provided
ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Study Chair: David Bates, PhD Bristol Heart Institute at University of Bristol
Eastern Cooperative Oncology Group
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP